Zydus gets final USFDA nod for Propafenone HCL ER capsules

Propafenone is known as an anti-arrhythmic drug.

66
Medicine
Picture: Pixabay

Zydus Cadila has received final approval from the USFDA to market Propafenone Hydrochloride Extended-Release Capsules USP, 225 mg, 325 mg, and 425 mg (US RLD: Rythmol Capsules).

Propafenone is known as an anti-arrhythmic drug. It works by blocking the activity of certain electrical signals in the heart that can cause an irregular heartbeat.

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 315 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.


Also read:

Caplin gets USFDA nod for Neostigmine Methylsulfate Injection

Gilead gets USFDA nod to treat metastatic urothelial cancer

NATCO gets tentative USFDA nod for Ibrutinib tablets

First AI device to help detect colon cancer gets USFDA nod

Aleor gets tentative USFDA nod for drug for topical treatment

Zydus Cadila gets final USFDA nod for drug to treat High…


Enter your email address:

Delivered by FeedBurner

Latest updates

The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Go to main website, click here

Follow and connect with us on Facebook and Linkedin

For daily free updates on WhatsApp, click here

Subscribe here for daily updates
Loading